Vidutolimod plus pembrolizumab as 2L+treatment in patients with antiePD-1erefractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study
ANNALS OF ONCOLOGY(2022)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined